Sign up USA
Proactive Investors - Run By Investors For Investors

Under Armour slips in pre-market as latest Steph Curry shoe late to the court

The Curry 4 was supposed to hit stores on Friday, but retailers are still only taking orders with a shipping date of November 18
steph curry
Under Armour is trying to challenge the dominance of Nike in the sports footwear market

Under Armour Inc’s (NYSE:UAA) push into the world of footwear has been dealt a fresh blow with the latest edition of its best-selling sneaker late to the course.

The Washington DC-based sportswear manufacturer had hoped that the Curry 4 – endorsed by NBA superstar Steph Curry (pictured) – would help it to bounce back from slowing growth and attack a market dominated by Nike Inc (NYSE:NKE).

READ: Under Armour under pressure as it cuts full year guidance and axes jobs

The adult version of the US$130 sneakers were supposed to hit stores on Friday, but Foot Locker Inc (NYSE:FL), Dicks Sports Goods Inc (NYSE:DKS) and other major retailers are still only allowing customers to order a pair with a shipping date of November 18.

Susquehanna Financial Group analyst Sam Poser said the stores “are not happy” with the delays, adding that the hotly-anticipated trainers might “become an afterthought” as punters move on to other things – namely the latest Nike shoe.

Poser claims the shoe is late due to “last-minute design changes”, although UA has reportedly denied this.

Under Armour’s Curry brand is the showpiece of its push into sneakers, but sales of the franchise have slowed over the past year and a poor outing from its latest kicks would only add to that.

“Disappointing revenue performance of the Curry 4 would be a major setback for Under Armour’s footwear plans,” Poser said.

In pre-market trade Under Armour shares were down 2.6% to US$15.62.

View full UA profile View Profile

Under Armour Timeline

September 09 2015

Related Articles

H&T Pawnbrokers store
November 15 2017
“We have delivered a strong trading performance during the second half in the key segments of Pawnbroking, Retail and Personal Loans”
Medical tests
July 11 2017
In an operational update, the medical services and software company said a multi-centre investigator led study comprising data from 607 patients at two academic university hospitals has now been completed

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use